306 filings
Page 3 of 16
8-K
9olk9 r2k2
18 Nov 21
The Lancet Neurology Publishes Pivotal Phase 3 PROPEL Study Results of AT-GAA in Late-Onset Pompe Disease
7:01am
8-K
qpzj7ggd5fp5 0u
9 Nov 21
Amicus Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Updates
7:07am
8-K
1lrf85f4zgqoasrca
29 Sep 21
Amicus Therapeutics and ARYA Sciences Acquisition Corp IV
9:28am
8-K
4e0tdyi53keej7glk9ve
5 Aug 21
Amicus Therapeutics Announces Second Quarter 2021 Financial Results and Corporate Updates
7:02am
8-K
9s3rlpyl
2 Aug 21
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
7:00am
8-K
w4gjhk yqk5oelh
14 Jun 21
Amicus Therapeutics Appoints Eiry W. Roberts, M.D. to its Board of Directors
7:27am
8-K
isk3vb1qp lqxqe5tc
8 Jun 21
Amicus Therapeutics Announces United Kingdom’s MHRA Grants Early Access to AT-GAA
7:00am
8-K
6q3aya3q0z
10 May 21
Amicus Therapeutics Announces First Quarter 2021 Financial Results and Corporate Updates
7:00am
8-K
twu2 81ua91
3 May 21
Amicus Therapeutics Announces Successful Pre-BLA Meeting with U.S. FDA for AT-GAA for the Treatment of Pompe Disease
7:01am
8-K
n0zd4fpgzxy2g
1 Mar 21
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates
12:00am
8-K
vgqnybu2 uhfx
11 Feb 21
Rolling BLA submission for AT-GAA planned for completion in Q2 and other global regulatory submissions for approval expected throughout 2021
4:01pm
8-K
ol2b0
8 Feb 21
Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease
2:30pm
8-K
8qrkkzbh
11 Jan 21
Amicus Therapeutics Reports Preliminary 2020 Revenue and Provides 2021 Outlook
7:00am
8-K
8q4umljpg
2 Dec 20
Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors
7:00am
8-K
ib2nbj g0ql2sy
5 Nov 20
Amicus Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
7:00am
8-K
e2gbigp01t 08lmdwtp
10 Aug 20
Amicus Therapeutics Announces Second Quarter 2020 Financial Results and Corporate Updates
7:00am
8-K
2xg9703
30 Jul 20
Termination of a Material Definitive Agreement
7:13pm
8-K
hnxvifm37k 16zxt
17 Jul 20
Amicus Therapeutics Secures $400 Million Non-Dilutive Debt Financing
7:33am
8-K
de8 7luures8vh9slry
8 Jun 20
Submission of Matters to a Vote of Security Holders
4:41pm
8-K
sesl9pud5kfb2
14 May 20
Other Events
7:00am